Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018

Jesús Berdeja • 5 Oct 2018
ESH MM 2018
Multiple Myeloma bb2121 CAR-T

CAR T-cells have gone from strength to strength in the field of hem-onc, and it looks like the next malignancy they are set to revolutionize treatment for is multiple myeloma (MM). We spoke to Jesús Berdeja, MD, of the Sarah Cannon Center for Blood Cancer, Nashville, TN, to find out more. Dr Berdeja discusses the current landscape for CAR T-cells in MM, with multiple agents currently in trials for which updates are expected at ASH 2018, including bb2121. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Jesús Berdeja

1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
4:10
Update on CARTITUDE-1: CAR-T in RRMM
Jesús Berdeja • 26 May 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals